Inhibition of TGF-β is thought to silence the over-activation of TGF-β signalling, which is involved in the regulation of bone mass and fractures in OI, and the use of anti-TGF-β antibodies allows bone mass to increase and therefore also improves bone strength [28,39]. This evidence concerns the gene TGFB1 and osteogenesis imperfecta.